TEVA Pharmaceutical Industries Limited
Teva was incorporated in Israel on February 13, 1944, and is the successor to a number of Israeli corporations, the oldest of which was established in 1901. Teva is the leading generic drug company in the world, as well as in the United States, in terms of both total and new prescriptions.
Teva global presence covers North America, Europe, Latin America, Asia and Israel. They currently have direct operations in more than 60 countries, including 38 finished dosage pharmaceutical manufacturing sites in 17 countries, 15 generic R centers operating mostly within certain manufacturing sites and 21 API manufacturing sites around the world. In 2009, we generated approximately 60% of our sales in North America (which for the purpose of this report includes the United States and Canada only), approximately 25% in Europe. We market over 400 generic products in more than 1,300 dosage strengths and packaging sizes. We also have the capability to formulate, fill, label and package finished dosage forms of injectable pharmaceutical products. generic pipeline, which, as of February 5, 2010, had 216 product registrations a prada waiting FDA approval (including some products through strategic partnerships), including 43 tentative approvals. sales in 2009 exceeding $113 billion. Of these applications, 140 were IV applications challenging patents of branded products. sales of more than $55 billion in 2009. This information and more was found here in the latest 20F r prada eport filed with the SEC.
Generic pharmaceuticals are the chemical and therapeutic equivalents of brand name drugs and are typically sold under their chemical names at prices substantially below those of the brand name pharmaceuticals. Generics are required to meet similar governmental regulations as their brand name equivalents and must receive regulatory approval prior to their sale in any given country.
Why are generic drugs important?
You are walking down the aisle at the grocery store when you stop your cart in the breakfast cereal aisle. Do you want to prada buy that colorful box of Fruit Loops with Toucan Sam on the cover staring at you on the eye level shelf or do you want to buy that bag of loops in the clear plastic bag on the shelf your feet? Now think about that choice if the loops were 33% the price, you are short on cash, or if you needed loops to live. Think about that choice if a government run Health Czar made the choice for you? When the country is running out of money, do you think the health czars will be giving you the expensive stuff, or the cheaper alternative that supposed to be just as good?
The monster trend is that the Western world is aging, and older people demand more health care. Not only are the people of the West getting older, but life expectancies are also increasing. So more people are getting old, and old people are getting even older. A company making generic drugs is worth its weight in gold.
Teva is in the right business, and Teva earnings are growing nicely.
2004: 1.46 EPS
2005: 1.59 EPS
2006: 2.30 EPS
2007: 2.38 EPS
2008: 2.86 EPS
2009: 3.37 EPS
2010: 4.57 EPS (projected)
2011: 5.08 EPS (project prada ed) which would equal a 10 to Earnings ratio. In the year 2000 the dividend was about a penny and a half per share per quarter. By 2007 they were up to about 10 cents per share per quarter and they are currently at about 18 cents per share per quarter. I plan on holding this stock a long time. Not 10 days or 4 months a long time for day traders, but for decades. I believe this company will continue to grow and outperform markets over the long term. I’m not looking to beat the market for 1 2 years, I am looking to beat the market over the long term and I believe TEVA is a good stock for the long term.
Buffet is known as a long term investor that sees the forest from the trees, and he recently increased his bet on health care companies. The company is in the right business for the foreseeable future. They make cheap drugs for an aging population, and they make them well. They have over 400 generic products with 216 more potential ones currently in the pipelines. The company is managed well financially, they do not have a lot of leverage, they are growing earnings, making strategic acquisitions, have a strong pipeline and are rewarding shareholders with a fast growing dividend. If the economy is to stay weak for the foreseeable future, health care is one thing that people can scrimp on due to inelastic demand. The price isn’t even expensive with an 11 PE for the current year and a 10 PE for next years projections, so what will their earnings be over the long term (Teva is a long term hold)? I am already long JNJ PFE, and a smaller growing drug company like TEVA is a good match with these bigger companies.